Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $308,685.28 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 133,054 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $308,685.28. Following the completion of the transaction, the chief executive officer directly owned 450,667 shares in the company, valued at approximately $1,045,547.44. The trade was a 22.79% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Joseph Oliveto also recently made the following trade(s):

• On Monday, January 26th, Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total value of $66,629.39.
• On Thursday, January 8th, Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.25, for a total transaction of $96,750.00.
• On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total value of $1,125.00.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST traded down $0.07 during trading on Wednesday, reaching $1.94. The company’s stock had a trading volume of 1,697,941 shares, compared to its average volume of 3,110,069. The firm has a market cap of $165.23 million, a price-to-earnings ratio of -2.37 and a beta of 0.44. The firm has a 50 day moving average of $2.23 and a 200-day moving average of $1.96. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. Milestone Pharmaceuticals Inc. has a 12 month low of $0.63 and a 12 month high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. Research analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on MIST. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Wells Fargo & Company upped their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Trending Headlines about Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Propel Bio Management LLC raised its stake in Milestone Pharmaceuticals by 186.1% during the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after buying an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC bought a new position in Milestone Pharmaceuticals in the 3rd quarter worth $6,444,000. Simplify Asset Management Inc. grew its holdings in Milestone Pharmaceuticals by 186.2% during the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after purchasing an additional 1,842,974 shares during the period. Pathstone Holdings LLC purchased a new stake in Milestone Pharmaceuticals in the third quarter worth about $2,000,000. Finally, Boxer Capital Management LLC bought a new position in shares of Milestone Pharmaceuticals in the third quarter worth about $1,333,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.